PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)

In this prospective, multicenter, open-label randomized controlled trial, 180 patients with ACS are randomized in a 1:1 ratio to either \"inclisiran early\" intensified therapy (early adding inclisiran to moderate-intensity statin therapy) group or guideline-directed medical therapy group for 12 months. Patients experience serial OCT of the non-culprit, non-flow-limiting arteries (target vessels) at baseline (culprit lesion procedure on admission) and at 12 months. The primary endpoint is the percentage of patients with vulnerable plaques in target vessels at 1 year post randomization.